International Journal of Cancer Management

Published by: Kowsar

Promoter Hypermethylation Analysis of the Tumor Suppressor Genes RASSF1A and RASSF2A in Iranian Endometrial Carcinoma Patients

Neda Jabbara 1 , Golnaz Asaadi Tehrani 1 , * , Fatemeh Lalooha 2 , Seyed Amir Farzam 3 and Khadijeh Elmizadeh 4
Authors Information
1 Department of Genetics, Faculty of Basic Sciences, Islamic Azad University, Zanjan Branch, Zanjan, Iran
2 Department of Obstetrics and Gynecology, Qazvin University of Medical Sciences, Qazvin, Iran
3 Department of Pathology, Medical Faculty, Qazvin University of Medical Sciences, Qazvin, IR Iran
4 Department of Obstetrics and Gynecology, Qazvin University of Medical Sciences, Qazvin, Iran
Article information
  • International Journal of Cancer Management: April 2017, 10 (4); e8629
  • Published Online: March 26, 2017
  • Article Type: Research Article
  • Received: September 1, 2016
  • Revised: October 8, 2016
  • Accepted: March 1, 2017
  • DOI: 10.5812/ijcm.8629

To Cite: Jabbara N, Asaadi Tehrani G, Lalooha F, Farzam S A, Elmizadeh K. Promoter Hypermethylation Analysis of the Tumor Suppressor Genes RASSF1A and RASSF2A in Iranian Endometrial Carcinoma Patients, Int J Cancer Manag. 2017 ; 10(4):e8629. doi: 10.5812/ijcm.8629.

Abstract
Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Intruduction
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4): 225-49[DOI][PubMed]
  • 2. Renaud MC, Le T, Le T, Bentley J, Farrell S, Fortier MP, et al. Epidemiology and investigations for suspected endometrial cancer. J Obstet Gynaecol Can. 2013; 35(4): 380-3[PubMed]
  • 3. Lutz JM, Francisci S, Mugno E, Usel M, Pompe-Kirn V, Coebergh JW, et al. Cancer prevalence in Central Europe: the EUROPREVAL Study. Ann Oncol. 2003; 14(2): 313-22[PubMed]
  • 4. Armstrong AJ, Hurd WW, Elguero S, Barker NM, Zanotti KM. Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol. 2012; 19(5): 562-71[DOI][PubMed]
  • 5. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012; 120(2 Pt 1): 383-97[DOI][PubMed]
  • 6. Lax S. [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology]. Pathologe. 2011; 32 Suppl 2: 255-64[DOI][PubMed]
  • 7. Tao MH, Freudenheim JL. DNA methylation in endometrial cancer. Epigenetics. 2010; 5(6): 491-8[PubMed]
  • 8. Di Domenico M, Santoro A, Ricciardi C, Iaccarino M, Iaccarino S, Freda M, et al. Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer Biol Ther. 2011; 12(5): 447-57[PubMed]
  • 9. Turek-Plewa J, Jagodzinski PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett. 2005; 10(4): 631-47[PubMed]
  • 10. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene. 2002; 21(35): 5462-82[DOI][PubMed]
  • 11. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res. 2004; 64(23): 8688-93[DOI][PubMed]
  • 12. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, et al. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol. 2002; 12(4): 253-65[PubMed]
  • 13. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene. 2002; 21(9): 1381-90[DOI][PubMed]
  • 14. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem. 2003; 278(30): 28045-51[DOI][PubMed]
  • 15. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK, et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol. 2004; 6(2): 129-37[DOI][PubMed]
  • 16. Dallol A, Agathanggelou A, Fenton SL, Ahmed-Choudhury J, Hesson L, Vos MD, et al. RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res. 2004; 64(12): 4112-6[DOI][PubMed]
  • 17. Hamilton DW, Lusher ME, Lindsey JC, Ellison DW, Clifford SC. Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett. 2005; 227(1): 75-81[DOI][PubMed]
  • 18. Rykova EY, Laktionov PP, Skvortsova TE, Starikov AV, Kuznetsova NP, Vlassov VV. Extracellular DNA in breast cancer: Cell-surface-bound, tumor-derived extracellular DNA in blood of patients with breast cancer and nonmalignant tumors. Ann N Y Acad Sci. 2004; 1022: 217-20[DOI][PubMed]
  • 19. Thaler S, Hahnel PS, Schad A, Dammann R, Schuler M. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res. 2009; 69(5): 1748-57[DOI][PubMed]
  • 20. Song MS, Song SJ, Kim SY, Oh HJ, Lim DS. The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J. 2008; 27(13): 1863-74[DOI][PubMed]
  • 21. Hesson L, Bieche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene. 2004; 23(13): 2408-19[DOI][PubMed]
  • 22. Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, et al. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene. 2005; 24(24): 3987-94[DOI][PubMed]
  • 23. Cooper WN, Hesson LB, Matallanas D, Dallol A, von Kriegsheim A, Ward R, et al. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene. 2009; 28(33): 2988-98[DOI][PubMed]
  • 24. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009; 1796(2): 114-28[DOI][PubMed]
  • 25. Wang Y, Yu Z, Wang T, Zhang J, Hong L, Chen L. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer. 2007; 56(2): 289-94[DOI][PubMed]
  • 26. Song H, Oh S, Oh HJ, Lim DS. Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity. Biochem Biophys Res Commun. 2010; 391(1): 969-73[DOI][PubMed]
  • 27. Heichman KA, Warren JD. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med. 2012; 50(10): 1707-21[DOI][PubMed]
  • 28. Hatzimichael E, Crook T. Cancer epigenetics: new therapies and new challenges. J Drug Deliv. 2013; 2013: 529312[DOI][PubMed]
  • 29. Pallares J, Velasco A, Eritja N, Santacana M, Dolcet X, Cuatrecasas M, et al. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol. 2008; 21(6): 691-9[DOI][PubMed]
  • 30. Foley DL, Craig JM, Morley R, Olsson CA, Dwyer T, Smith K, et al. Prospects for epigenetic epidemiology. Am J Epidemiol. 2009; 169(4): 389-400[DOI][PubMed]
  • 31. Qian ZR, Sano T, Yoshimoto K, Yamada S, Ishizuka A, Mizusawa N, et al. Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest. 2005; 85(4): 464-73[DOI][PubMed]
  • 32. Pan ZG, Kashuba VI, Liu XQ, Shao JY, Zhang RH, Jiang JH, et al. High frequency somatic mutations in RASSF1A in nasopharyngeal carcinoma. Cancer Biol Ther. 2005; 4(10): 1116-22[PubMed]
  • 33. Matthaios D, Balgkouranidou I, Karayiannakis A, Bolanaki H, Xenidis N, Amarantidis K, et al. Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. Oncol Lett. 2016; 12(1): 748-56[DOI][PubMed]
  • 34. Bae YK, Shim YR, Choi JH, Kim MJ, Gabrielson E, Lee SJ, et al. Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res Treat. 2005; 37(4): 233-40[DOI][PubMed]
  • 35. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001; 61(4): 1659-65[PubMed]
  • 36. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, et al. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol. 2008; 14(19): 3074-80[PubMed]
  • 37. Yazici H, Terry MB, Cho YH, Senie RT, Liao Y, Andrulis I, et al. Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2009; 18(10): 2723-5[DOI][PubMed]
  • 38. Seeber LM, Zweemer RP, Marchionni L, Massuger LF, Smit VT, van Baal WM, et al. Methylation profiles of endometrioid and serous endometrial cancers. Endocr Relat Cancer. 2010; 17(3): 663-73[DOI][PubMed]
  • 39. Arafa M, Kridelka F, Mathias V, Vanbellinghen JF, Renard I, Foidart JM, et al. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology. 2008; 53(5): 525-32[DOI][PubMed]
  • 40. Liao X, Siu MK, Chan KY, Wong ES, Ngan HY, Chan QK, et al. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer. 2008; 123(2): 296-302[DOI][PubMed]
  • 41. Kang S, Lee JM, Jeon ES, Lee S, Kim H, Kim HS, et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer. 2006; 119(6): 1316-21[DOI][PubMed]
  • 42. Kang S, Kim JW, Kang GH, Lee S, Park NH, Song YS. Comparison of DNA hypermethylationpatterns in different types of uterine cancer, cervicalsquamous cell carcinoma, cervical adenocarcinoma andendometrial adenocarcinoma. Int J Cancer. 2006; 118: 2168-71
  • 43. Fiolka R, Zubor P, Janusicova V, Visnovsky J, Mendelova A, Kajo K, et al. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer. Oncol Rep. 2013; 30(6): 2878-86[DOI][PubMed]
  • 44. Hesson LB, Latif F. RASSF2 (Ras association (RalGDS/AF-6) domain family member 2). Oncol Haematol. 2010; 14(7): 652-61
  • 45. Meng W, Huebner A, Shabsigh A, Chakravarti A, Lautenschlaeger T. Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer. Mol Biol Int. 2012; 2012: 701814[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments